



**State of Louisiana**  
Louisiana Department of Health  
Bureau of Health Services Financing

**MEMORANDUM**

**DATE:** March 17, 2025

**TO:** All Louisiana Medicaid Prescribing Providers and Pharmacists

**FROM:** Kimberly Sullivan, Medicaid Executive Director *KLS*

**SUBJECT:** Louisiana Medicaid Pharmacy Point of Sale  
Maximum Daily Dose and Quantity Limits *Revised*– March 2025

Effective March 1, 2025, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement new Point of Sale (POS) quantity limits. These quantity limits will apply to pharmacy claims submitted to Gainwell Technologies for FFS and to Prime Therapeutics, LLC for MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, and UnitedHealthcare).

**Point of Sale Edits:**

**1.) Exceeding the Maximum Allowable Daily Dose for Oral Buprenorphine Agents**

Pharmacy claims submitted for oral buprenorphine that exceed the maximum daily dose of 24mg/day will reject with the following:

- Denial from Gainwell Technologies (FFS Only): NCPDP rejection code 88 (DUR Reject Error) mapped to **EOB Code 325** (Exceeds Max Daily Dose MD Fax Form to 866-797-2329)
- Denial from Prime Therapeutics, LLC (MCO Only): NCPDP rejection error 76 mapped to internal error code 2709. Exceeds maximum daily dose of 24mg/day.

**Note:** A prior authorization approval for exceeding the maximum allowable dose will allow up to 32mg buprenorphine or buprenorphine equivalent (e.g., Zubsolv 5.7mg/1.4mg).

## 2.) Quantity Limits

Pharmacy claims that exceed the maximum quantity limit, will deny at POS with:

- Denial from Gainwell Technologies (FFS Only): **NCPDP rejection error 76** (Quantity and/or days' supply exceeds program maximum) mapped to **EOB Code 457** (Quantity and/or days' supply exceeds program maximum).
- Denial from Prime Therapeutics, LLC (MCO Only): **NCPDP rejection code 76** (Quantity and/or days' supply exceeds program maximum) **mapped to an internal error code 15110.**

Override (FFS Only): Upon consultation with the prescriber to verify medical necessity of excessive quantity, the pharmacist may override the denial by submitting the following override codes at POS:

- **NCPDP 439-E4 Field** (Reason for Service Code) - **EX** (Excessive Quantity)
- **NCPDP 440-E5 Field** (Professional Service Code) - **MØ** (Prescriber Consulted)
- **NCPDP 441-E6 Field** (Result of Service Code) - **1G** (Filled with Prescriber Approval)

Override (MCO Only): The override procedure will be a PA process. The pharmacy will not be able to override the quantity limit at POS using **NCPDP override codes**.

The agents listed in the following chart have a quantity limit at Point of Sale (POS).

| Medications                                         | Specific Indications (if applicable)                                     | Quantity Limit                           |
|-----------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------|
| Colchicine 0.5mg tablet (Lodoco®)                   |                                                                          | One (1) tablet per day                   |
| Lisdexamfetamine capsule/chewable tablet (Vyvanse®) |                                                                          | 30 capsules/chewable tablets per 30 days |
| Linaclotide capsule (Linzess®)                      |                                                                          | One (1) capsule per day                  |
| Mupirocin 2% Cream/Ointment                         |                                                                          | 60 gm per 30 days                        |
| Paliperidone Palmitate (Erzofri™)                   |                                                                          | 1 unit every 28 days                     |
| Perfluorohexyloctane (Miebo®)                       |                                                                          | One (1) 3ml bottle as a 30-day supply    |
| Sitagliptin tablet (Januvia®)/Zituvio®)             | <i>Note: Quantity limit edit will replace current maximum dose edit.</i> | 30 tablets per 30 days                   |
| Xanomeline Tartrate/Trospium Chloride (Cobenfy™)    |                                                                          | 60 capsules per 30 days                  |

LA Medicaid Pharmacy Point of Sale Maximum Daily Dose and Quantity Limits

Revised- March 2025

March 17, 2025

Page 3

| <b>Asthma/COPD – Glucocorticoids, Inhalation</b>                          |  | <b>Quantity Limit</b>        |
|---------------------------------------------------------------------------|--|------------------------------|
| Albuterol/Budesonide (AirSupra HFA®)                                      |  | Two (2) inhalers per 30 days |
| Beclomethasone Breath-Actuated HFA (QVAR® RediHaler®)                     |  | Two (2) inhalers per 30 days |
| Budesonide DPI (Pulmicort® Flexhaler®)                                    |  | Two (2) inhalers per 30 days |
| Budesonide Respules 0.25 mg, 0.5 mg, 1 mg (Generic; Pulmicort® Respules®) |  | Two (2) doses per day        |
| Budesonide/Formoterol MDI (AG; Generic; Symbicort®)                       |  | One (1) inhaler per 30 days  |
| Budesonide/Glycopyrrolate/Formoterol Inhalation (Breztri Aerosphere™)     |  | One (1) inhaler per 30 days  |
| Ciclesonide MDI (Alvesco®)                                                |  | One (1) inhaler per 30 days  |
| Fluticasone Furoate Inhalation Powder (Arnuity Ellipta®)                  |  | One (1) inhaler per 30 days  |
| Fluticasone MDI (AG; Flovent® HFA)                                        |  | Two (2) inhalers per 30 days |
| Fluticasone Propionate Inhalation Powder (Armonair® Digihaler™)           |  | One (1) inhaler per 30 days  |
| Fluticasone Propionate Inhalation Powder (Flovent® Diskus®)               |  | One (1) inhaler per 30 days  |
| Fluticasone/Salmeterol DPI (AG; Generic; Advair® Diskus®, Wixela Inhub®)  |  | One (1) inhaler per 30 days  |
| Fluticasone/Salmeterol Inhalation Powder (AG; AirDuo® RespiClick®)        |  | One (1) inhaler per 30 days  |
| Fluticasone/Salmeterol Inhalation Powder (AirDuo® Digihaler™)             |  | One (1) inhaler per 30 days  |
| Fluticasone/Salmeterol MDI (AG; Advair HFA®)                              |  | One (1) inhaler per 30 days  |
| Fluticasone/Umeclidinium/Vilanterol Inh Powder (Trelegy Ellipta®)         |  | One (1) inhaler per 30 days  |
| Fluticasone/Vilanterol Inhalation Powder (AG; Breo Ellipta®)              |  | One (1) inhaler per 30 days  |
| Mometasone Furoate MDI (Asmanex HFA®)                                     |  | One (1) inhaler per 30 days  |
| Mometasone Inhalation Powder (Asmanex® Twisthaler®)                       |  | One (1) inhaler per 30 days  |
| Mometasone/Formoterol MDI (Dulera®)                                       |  | One (1) inhaler per 30 days  |
|                                                                           |  |                              |

LA Medicaid Pharmacy Point of Sale Maximum Daily Dose and Quantity Limits

Revised- March 2025

March 17, 2025

Page 4

| <b>Hypoglycemics: Insulin &amp; Related Agents</b>                   |  | <b>Quantity Limit</b> |
|----------------------------------------------------------------------|--|-----------------------|
| Insulin Aspart Cartridge, Pen (AG; Novolog®)                         |  | 45 mL per 30 days     |
| Insulin Aspart Vial (AG; Novolog®)                                   |  | 50 mL per 30 days     |
| Insulin Aspart Protamine/Aspart Pen (AG; Novolog Mix 70/30®)         |  | 45 mL per 30 days     |
| Insulin Aspart Protamine/Aspart Vial (AG; Novolog Mix 70/30®)        |  | 50 mL per 30 days     |
| Insulin Glargine Pen (Generic; Lantus® SoloStar®)                    |  | 45 mL per 30 days     |
| Insulin Glargine Vial (Generic; Lantus®)                             |  | 50 mL per 30 days     |
| Insulin Glulisine Pen (Apidra® SoloStar®)                            |  | 45 mL per 30 days     |
| Insulin Glulisine Vial (Apidra®)                                     |  | 50 mL per 30 days     |
| Insulin Vial OTC (Humulin® N; Humulin® R)                            |  | 50 mL per 30 days     |
| Insulin Regular 500 units/mL Pen (Humulin® R U-500)                  |  | 18 ml per 30 days     |
| Insulin Regular 500 units/mL Vial (Humulin® R U-500)                 |  | 20 ml per 30 days     |
| Insulin Isophane (NPH)/Insulin Regular Pen OTC (Humulin® 70/30)      |  | 45 mL per 30 days     |
| Insulin Isophane (NPH)/Insulin Regular Vial OTC (Humulin® 70/30)     |  | 50 mL per 30 days     |
| Insulin Lispro (AG; Humalog® Junior KwikPen®)                        |  | 45 mL per 30 days     |
| Insulin Lispro Cartridge (Humalog®)                                  |  | 45 mL per 30 days     |
| Insulin Lispro Pen (AG; Humalog® KwikPen® U-100)                     |  | 45 mL per 30 days     |
| Insulin Lispro Vial (AG; Humalog®)                                   |  | 50 mL per 30 days     |
| Insulin Lispro Protamine/Insulin Lispro KwikPen (AG)                 |  | 45 mL per 30 days     |
| Insulin Lispro Protamine/Insulin Lispro Pen (Humalog® Mix)           |  | 45 mL per 30 days     |
| Insulin Lispro Protamine/Insulin Lispro Vial (Humalog® Mix)          |  | 50 mL per 30 days     |
| Insulin Aspart Cartridge, Pen (Fiasp® Penfill®/PumpCart®/FlexTouch®) |  | 45 mL per 30 days     |
| Insulin Aspart Vial (Fiasp®)                                         |  | 50 mL per 30 days     |
| Insulin Degludec Pen (Generic; Tresiba® FlexTouch®)                  |  | 45 mL per 30 days     |
| Insulin Degludec Vial (Generic; Tresiba®)                            |  | 50 mL per 30 days     |

LA Medicaid Pharmacy Point of Sale Maximum Daily Dose and Quantity Limits

Revised- March 2025

March 17, 2025

Page 5

|                                                                          |  |                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Insulin Detemir Pen (Levemir®)                                           |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Detemir Vial (Levemir®)                                          |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Glargine U-100 (Basaglar® KwikPen®; Basaglar® Tempo Pen™)        |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Glargine-aglr (Rezvoglar® KwikPen®)                              |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Glargine-yfgn Pen (Generic; Semglee®)                            |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Glargine-yfgn Vial (Generic; Semglee®)                           |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Glargine Pen (Generic; Toujeo® Solostar®, Toujeo® Max Solostar®) |  | 9 mL per 30 days                                                                                                                                                                                                                                     |
| Insulin Lispro Pen (Admelog® SoloStar®)                                  |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Lispro Vial (Admelog®)                                           |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Lispro Pen (Humalog® KwikPen® U-200; Humalog® Tempo Pen™ U-100)  |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Lispro-aabc Pen (Lyumjev® KwikPen®; Lyumjev® Tempo Pen™)         |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Lispro-aabc Vial (Lyumjev®)                                      |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Isophane (NPH)/Insulin Regular Pen OTC (Novolin® 70/30)          |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Isophane (NPH)/Insulin Regular Vial OTC (Novolin® 70/30)         |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Human Pen OTC (Novolin® N; Novolin® R)                           |  | 45 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Human Vial OTC (Novolin® N; Novolin® R)                          |  | 50 mL per 30 days                                                                                                                                                                                                                                    |
| Insulin Human Inhalation Powder Cartridge (Afrezza®)                     |  | 4 unit: 9 cartridges per day<br>8 unit: 6 cartridges per day<br>12 unit: 3 cartridges per day<br>4 & 8 unit: 6 cartridges per day*<br>4, 8, & 12 unit: 6 cartridges per day*<br>8 & 12 unit: 6 cartridges per day*<br><br>*Allow 1 fill per 180 days |
| Insulin Human Pen OTC (Humulin® N Kwikpen® U-100)                        |  | 45 mL per 30 days                                                                                                                                                                                                                                    |

LA Medicaid Pharmacy Point of Sale Maximum Daily Dose and Quantity Limits

Revised- March 2025

March 17, 2025

Page 6

**Additional Information:**

Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form*, medication list, criteria, and diagnosis code list.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

FFS pharmacy claims should be submitted to Gainwell Technologies. MCO pharmacy claims should be submitted to Prime Therapeutics, LLC.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

| Healthcare Provider                                                                                                   | Pharmacy Help Desk      | Pharmacy Help Desk Phone Number |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------|
| Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, UnitedHealthcare | Prime Therapeutics, LLC | (800) 424-1664                  |
| Fee for Service                                                                                                       | Gainwell Technologies   | (800) 648-0790                  |

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

KS/MBW/GJS

c: Gainwell Technologies  
Healthy Louisiana Plans  
Kolynda Parker  
Melwyn B. Wendt  
Prime Therapeutics, LLC